Next Article in Journal
B Cells Isolated from Individuals Who Do Not Respond to the HBV Vaccine Are Characterized by Higher DNA Methylation-Estimated Aging Compared to Responders
Previous Article in Journal
Vaccination with Tozimameran Induces T-Cell Activation, but Not Senescent or Exhaustive Alterations, in Kidney Transplant Recipients
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 12
Issue 8
10.3390/vaccines12080879
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Systematic Review

Efficacy, Safety, and Immunogenicity of Subunit Respiratory Syncytial Virus Vaccines: Systematic Review and Meta-Analysis of Randomized Controlled Trials

by
Yuhang Wu
†,
Yuqiong Lu
†,
Yuwei Bai
,
Bingde Zhu
,
Feng Chang
*,‡ and
Yun Lu
*,‡
School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, China
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
‡
These authors also contributed equally to this work.
Vaccines 2024, 12(8), 879; https://doi.org/10.3390/vaccines12080879
Submission received: 22 June 2024 / Revised: 23 July 2024 / Accepted: 24 July 2024 / Published: 2 August 2024
Browse Figures
Review Reports Versions Notes

Abstract

:
Background: Respiratory syncytial virus (RSV) is garnering increasing attention, with a growing number of subunit RSV vaccines under active clinical investigation. However, comprehensive evidence is limited. Methods: We conducted a comprehensive search across PubMed, Embase, the Cochrane Library, Web of Science, and ClinicalTrials.gov from database inception to 12 January 2024, focusing on published randomized controlled trials (RCTs). Results: A total of 17 studies were included, encompassing assessments of efficacy (5 studies), safety (17 studies), and immunogenicity (12 studies) of RSV subunit vaccines. The pooled risk ratio (RR) for RSV-associated acute respiratory infection (RSV-ARI) with subunit vaccines was 0.31 (95% CI: 0.23–0.43), for RSV-associated lower respiratory tract infection (RSV-LRTI), it was 0.32 (95% CI: 0.22–0.44), and for severe RSV-LRTI (RSV-SLRTI), it was 0.13 (95% CI: 0.06–0.29). There was no significant difference in serious adverse events (SAEs) between the vaccine and placebo groups, with a pooled RR of 1.05 (95% CI: 0.98–1.14). The pooled standardized mean difference (SMD) for the geometric mean titer (GMT) of neutralizing antibodies was 2.89 (95% CI: 2.43−3.35). Conclusion: Subunit RSV vaccines exhibit strong efficacy, favorable safety profiles, and robust immunogenicity. Future research should focus on the cost-effectiveness of various vaccines to enhance regional and national immunization strategies.

1. Introduction

Respiratory syncytial virus (RSV) is a widespread respiratory pathogen that affects individuals of all ages, with significant consequences for vulnerable groups such as young children, the elderly, and those with weakened immune systems [1,2]. RSV is a leading cause of acute lower respiratory tract infections. Recent data from 2019 indicate that around 33 million children under five worldwide were affected by acute lower respiratory tract infections due to RSV, resulting in 3.6 million hospitalizations and 26,300 in-hospital deaths [3]. Furthermore, research by Savic (2023) highlights that in 2019, RSV was responsible for 470,000 hospitalizations and 33,000 deaths among the elderly population aged 60 and above in high-income countries [4]. The substantial burden of disease imposed by RSV is evident. Given that the majority of RSV-related fatalities occur outside hospital settings, the actual burden is likely underreported [5,6].
Currently, there are no specific antiviral therapies available for the treatment of RSV infection, with post-infection management relying primarily on supportive care [7]. Therefore, the prevention of RSV is significant. Preventive measures against RSV include the administration of monoclonal antibody medications and vaccines. Palivizumab and nirsevimab are the monoclonal antibodies currently approved for RSV prevention, though their use is restricted to infants. However, the high cost of palivizumab presents a substantial financial burden for low- and middle-income families, and the cost-effectiveness of nirsevimab remains to be established [8]. Consequently, in light of the limitations associated with monoclonal antibodies, the development of vaccines targeting RSV has become increasingly crucial.
RSV candidate vaccines utilize various strategies, including recombinant vector vaccines, subunit vaccines, particle vaccines, live attenuated vaccines, chimeric vaccines, and nucleic acid vaccines [9]. Among these, subunit vaccines were the first to reach clinical application. In May and June 2023, the FDA approved two subunit vaccines for preventing RSV infection in older adults: Arexvy (GlaxoSmithKline, London, UK) and Abrysvo (Pfizer Inc., New York, USA). Furthermore, Abrysvo has also been approved for preventing RSV in infants and young children. Both vaccines have been endorsed by the Advisory Committee on Immunization Practices (ACIP) for use in individuals aged 60 and older [10].
Simoes EA (2001) [11] conducted the first systematic review on subunit RSV vaccines, focusing on the safety data of the purified F protein subunit (PFP) vaccine [11]. Shan J (2021) [12] provided a descriptive summary of the safety and immunogenicity data of RSV candidate vaccines, finding that subunit vaccines demonstrated good safety profiles and elicited strong immune responses [12]. Currently, no studies have analyzed the efficacy of subunit vaccines, and there have been no quantitative evaluations of various indicators. With the increasing number of subunit vaccines entering RCTs, further evidence of their efficacy, safety, and immunogenicity in preventing RSV infection is necessary.
This study aims to conduct a systematic review and meta-analysis of the efficacy, safety, and immunogenicity of subunit vaccines in preventing RSV infection. RCTs will be analyzed to compare vaccinated individuals with placebo controls. Efficacy will be measured using the RR for RSV-related infections, immunogenicity using the SMD for neutralizing antibody titers, and safety by the incidence of adverse events. This comprehensive evaluation is essential for healthcare professionals to understand the overall benefits and risks associated with these vaccines, enabling them to make evidence-based decisions and optimize immunization strategies for better public health outcomes.

2. Methods

The protocol for this study has been registered with PROSPERO under the registration number CRD42024524720. This study adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist for systematic reviews and meta-analyses [13].

2.1. Search Strategy

For this systematic review and meta-analysis, a comprehensive search was conducted across PubMed, Embase, the Cochrane Library, Web of Science, and ClinicalTrials.gov, covering all studies published up to 12 January 2024. We utilized a combination of six terms and their synonyms, using both Medical Subject Headings (MeSHs) and free-text terms: respiratory syncytial virus, respiratory tract infection, vaccine, vaccination, subunit vaccine, and randomized controlled trial. The search strategy for PubMed, which can be adapted for other databases, is outlined in Table S1.

2.2. Study Selection

The inclusion and exclusion criteria are based on the PICOS principles. The inclusion criteria are as follows: (1) no restrictions on the study population; (2) the intervention is a subunit respiratory syncytial virus vaccine; (3) the control measure is placebo; (4) studies that include relevant outcome measures of RSV vaccine efficacy, safety, or immunogenicity; (5) RCTs.
The exclusion criteria are defined as follows: (1) studies that involve the combined use of other vaccines; (2) non-original research such as conference abstracts, reviews, meta-analyses, etc.; (3) studies conducted on animal or in vitro models and cell lines; (4) studies from which data could not be extracted despite efforts to contact the authors; (5) duplicate publications; (6) studies published in languages other than English.

2.3. Data Extraction and Outcome Measures

The study involved two researchers (BYW and ZBD) who independently extracted the data. Any disagreements were discussed and resolved with a third researcher (WYH). We used Microsoft Excel to construct a standardized data extraction form to record the extracted information, including (1) basic information: first author and publication year; (2) study characteristics: country/region, sample size, blinding method, study phase, and funding sources; (3) participant information: age range and gender ratio; (4) intervention information: the name of the vaccine in the intervention group, dosage, and whether the vaccine contained adjuvants; (5) outcome information: relevant outcomes of efficacy, safety, and immunogenicity, as well as follow-up time.
For dose exploration studies with multiple intervention groups, we included only those using the standard dose, defined as the dose of an approved vaccine product or the dose selected for phase III trials. According to WHO Preferred Product Characteristics for Respiratory Syncytial Virus Vaccines and the frequency of current mainstream vaccines, we only included outcome events after the first dose of the vaccine. As neutralizing antibody levels typically peak approximately one month after receiving a subunit vaccine, we considered only the neutralizing antibody data one month post-vaccination. When detailed information on outcomes was incomplete, we contacted the study authors directly or used data extraction software (GetData Graph Digitizer 2.22) to extract data from the original literature.
Primary outcome measures included the following: (1) efficacy, defined as RSV acute respiratory infection (RSV-ARI), acute lower respiratory tract infection (RSV-LRTI), and severe acute lower respiratory tract infection (RSV-SLRTI); (2) immunogenicity, assessed by neutralizing antibody titers; and (3) vaccine safety, evaluated by serious adverse events. Secondary outcome measures included the analysis of any local adverse events, any systemic adverse events, and specific adverse events such as redness at the injection site, pain at the injection site, swelling at the injection site, fever, headaches, fatigue, muscle pain, joint pain, nausea or vomiting, and chills.

2.4. Quality Assessment

We used the Cochrane Collaboration tool (RoB 2) to assess the risk of bias for randomized trials [14]. This tool evaluates several types of biases, including selection bias, performance bias, detection bias, attrition bias, and reporting bias, which helps in identifying potential sources of bias that might affect the validity of the trial results. The quality of evidence for the primary outcomes was evaluated using the Grade of Recommendation, Assessment, Development, and Evaluation (GRADE) system [15]. The GRADE system assesses evidence quality across five domains: study limitations (risk of bias), imprecision (the degree of certainty around the effect estimate), inconsistency (variability in results across studies), indirectness (differences in study population, intervention, comparator, or outcomes), and publication bias (selective publication of studies). These tools were chosen because they provide a systematic and transparent framework for evaluating the reliability and relevance of evidence from clinical trials, ensuring that the conclusions drawn are well supported and credible.

2.5. Data Analysis

This meta-analysis was performed using Stata 18.0 software. Efficacy and safety outcomes, being binary variables, were expressed as relative risk (RR) with 95% confidence intervals (CIs). Studies with no events in both the vaccination and control groups were excluded from the RR summary [16]. For studies where only one group had no events, a fixed value of 0.5 was added to each cell of the 2 × 2 table to correct for continuity [16]. Heterogeneity among the included studies was assessed using the I2 statistic. A random-effects model was applied when I2 exceeded 50%, whereas a fixed-effects model was utilized when I2 was 50% or less.
Immunogenicity outcomes are continuous variables with different units; hence, we used the standardized mean difference (SMD) of log-transformed geometric mean titers (GMTs) and the corresponding 95% CIs to represent the difference in immunogenicity between the vaccination and control groups. The SMD was calculated based on the DerSimonian–Laird model using the means and standard deviations of the two groups, with missing standard deviations estimated from the confidence intervals and sample sizes [16].
This study planned to conduct subgroup analyses based on age demographics (older adults, adults, children) and the inclusion of adjuvants in vaccines to identify potential heterogeneity sources. We utilized funnel plot asymmetry and the Egger test to evaluate potential publication bias. However, the publication bias test was omitted when fewer than 10 studies were included. Additionally, sensitivity analyses were carried out to assess the influence of individual studies on the overall estimates. In this study, a p-value of less than 0.05 was regarded as statistically significant.

3. Results

3.1. Search Results and Study Characteristics

We identified a total of 14,872 records, of which 3231 were duplicates and subsequently excluded. After screening the titles and abstracts of the remaining 11,641 studies, 71 studies met the inclusion criteria. The studies excluded after the full-text screening and the reasons for their exclusion are detailed in Table S2. Following a full-text review, data from 17 studies were included in the analysis (Figure 1) [17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33].
Table 1 summarizes the basic characteristics of the included studies. Overall, eight studies were multicenter trials that included participants with diverse age characteristics; six studies of subunit vaccines contained adjuvants, while eleven did not. All eligible studies were phase I/II to phase III RCTs; no phase IV studies were reported. Efficacy data were reported in five studies, vaccine safety was addressed in seventeen studies, and twelve studies provided information on vaccine immunogenicity.

3.2. Quality Assessment

For the three different efficacy outcomes, eight studies were assessed as having a moderate risk of bias, and one study was assessed as having a low risk of bias. For the immunogenicity outcomes, one study was rated as high risk, seven studies as moderate risk, and four studies as low risk. For the safety outcomes, one study was rated as high risk, three studies as moderate risk, and eight studies as low risk (Table S3).

3.3. The Efficacy of RSV Subunit Vaccines

Three studies were included to evaluate the efficacy of RSV-ARI [20,27,33], as shown in Figure 2. The overall impact of vaccination on acute respiratory infections favored the vaccine group, with a combined risk ratio of 0.31 (95% CI: 0.23–0.43, I2 = 0%), and no statistically significant heterogeneity was observed (p = 0.612). According to the GRADE system, the quality of evidence for the vaccine’s efficacy against RSV-ARI is considered moderate (Table S3).
Four studies were included to evaluate the efficacy of RSV-LRTI [21,27,31,33], as shown in Figure 3. The results show that the overall impact of vaccination on lower respiratory tract infections favored the vaccine group, with a combined risk ratio of 0.32 (95% CI: 0.22–0.44, I2 = 0%), and no statistically significant heterogeneity was observed (p = 0.200). According to the GRADE system, the quality of evidence for the vaccine’s efficacy against RSV-LRTI is considered moderate (Table S4).
Three studies were included to evaluate the efficacy of RSV-SLRTI [21,27,31], as shown in Figure 4. The results show that the overall impact of vaccination on severe lower respiratory tract infections favored the vaccine group, with a combined risk ratio of 0.13 (95% CI: 0.06–0.29, I2 = 0%), and no statistically significant heterogeneity was observed (p = 0.535). According to the GRADE system, the quality of evidence for the vaccine’s efficacy against RSV-SLRTI is considered moderate (Table S3).
Subgroup and sensitivity analyses were performed for the three efficacy outcomes. The subgroup analyses were based on the age of the subjects and the presence of adjuvants in the vaccine. While the results differed from the original outcomes, no statistically significant differences were noted (p > 0.05), as shown in Figure S1A–E. The sensitivity analysis revealed that no individual study significantly impacted the results, indicating the robustness of the findings, as shown in Figure S2A–C.

3.4. The Safety of RSV Subunit Vaccines

All 17 studies assessed safety outcomes, including any local adverse events, systemic adverse events, and serious adverse events. The risk of experiencing any local adverse events (RR = 3.58, 95% CI: 2.00–6.41) and any systemic adverse events (RR = 1.40, 95% CI: 1.05–1.85) was significantly higher in the vaccine group compared to the placebo group (Table 2). Specifically, the risk of local adverse events (such as pain, redness, and swelling at the injection site) in the vaccine group (RR = 3.75–5.49) exceeded that of systemic adverse events (RR = 1.05–1.91). Only one study reported the occurrence of chills post-vaccination, with an incidence of 6/100 in the vaccine group and 3/101 in the placebo group, thus precluding a meta-analysis [26].
The risk of serious adverse events is a key focus for vaccine safety. Twelve studies were included to assess serious adverse events following vaccination [17,19,20,21,22,26,27,29,30,31,32,33], as shown in Figure 5. The results show no significant difference in the incidence of serious adverse events between the vaccine group and the placebo group (RR = 1.05, 95% CI: 0.98–1.14). According to the GRADE system, the quality of evidence for serious adverse events is considered moderate (Table S3).
Subgroup analyses were performed considering the age characteristics of the participants and the presence of adjuvants in the vaccine. The results align with the overall findings, showing no statistically significant differences across subgroups (p > 0.05), as depicted in Figure S3A,B. The sensitivity analysis confirmed the robustness of the results, with no significant publication bias detected by the funnel plot and Egger’s test (p = 0.929), as illustrated in Figures S4 and S5.

3.5. Immunogenicity of RSV Subunit Vaccines

Twelve studies were included to evaluate immunogenicity following vaccination [17,20,22,23,25,26,27,28,30,31,32], as shown in Figure 6. The standardized mean difference (SMD) for the geometric mean titers (GMTs) of neutralizing antibodies post-vaccination was 2.89 (95% CI: 2.43−3.35). According to the GRADE system, the quality of evidence for neutralizing antibodies is considered low (Table S3).
The subgroup analysis showed that elderly subjects produced higher levels of neutralizing antibodies compared to the other two groups (SMD = 3.6), and the subgroup of vaccines containing adjuvants generated higher levels of neutralizing antibodies compared to those without adjuvants (SMD = 4.24), as shown in Figure S6. The sensitivity analysis indicated that no single included study significantly affected the immunogenicity results. The slightly asymmetrical funnel plot and Egger’s test did not reveal significant publication bias (p = 0.134), as illustrated in Figures S7 and S8.

4. Discussion

This systematic review and meta-analysis provides evidence on the efficacy, safety, and immunogenicity of subunit vaccines targeting respiratory syncytial virus. Our findings indicate that the following: (1) subunit vaccines are highly effective in preventing severe RSV-associated lower respiratory tract infections, with a pooled relative risk of 0.13 (Figure 4); (2) there is no significant difference in the incidence of serious adverse events between vaccine recipients and placebo groups, with a pooled RR of 1.05 (Figure 5); (3) subunit vaccines markedly enhance neutralizing antibody levels in participants, with a standardized mean difference of 2.89 (Figure 6). The subgroup analyses based on age and adjuvant inclusion showed consistent results, and the sensitivity analyses confirmed that excluding any single study did not change the overall findings. These analyses support the robustness of the results, suggesting that subunit vaccines are viable candidates for clinical application, albeit with careful consideration of local adverse reactions induced by the vaccines (RR = 3.75–5.49) (Table 2).
Currently, there is no consensus on the standardized methods for evaluating RSV vaccine efficacy endpoints, leading to variability in outcome measures across different RCTs [34]. Therefore, we included three different outcome indicators—acute respiratory infections (ARIs), lower respiratory tract infections (LRTIs), and severe lower respiratory tract infections (SLRTIs)—to comprehensively assess the efficacy of the vaccine. In a previous study that used patient-reported outcomes to confirm vaccine endpoint efficacy, ARIs and LRTIs were considered reliable outcome indicators [35]. Additionally, these three indicators have been recognized by the WHO. Our analysis revealed that subunit vaccines achieved an 87% efficacy in preventing severe RSV infections, surpassing the WHO’s benchmark of 70% effectiveness [36]. The efficacy against RSV-induced ARIs and LRTIs was 69% and 68%, respectively, closely aligning with the expected effectiveness. These findings underscore the potential of subunit vaccines in effectively preventing RSV infections.
Regarding vaccine safety, subunit vaccines are linked to a higher risk of local and systemic adverse events; however, there is no significant difference in the incidence of serious adverse events compared to the placebo group, consistent with previous studies [11,12]. The subgroup analysis also indicated no significant differences in the incidence of serious adverse events across different age groups, suggesting that the safety profile of subunit vaccines is acceptable.
Regarding immunogenicity, the failure of RSV vaccine development has often been attributed to insufficient immunogenicity [33]. In this study, we selected neutralizing antibody titers as the primary immunogenicity indicator, as research has demonstrated that the level of neutralizing antibodies is a critical determinant of vaccine efficacy [37]. Our findings indicate that subunit vaccines significantly increase neutralizing antibody levels compared to placebo. However, there was considerable heterogeneity in the results, potentially due to several factors. Firstly, the varying quality of studies may significantly influence the outcomes (one study on neutralizing antibody outcomes was rated as high, and seven were rated as moderate). Secondly, previous immune responses should be taken into account when assessing the immunogenicity of adult RSV vaccines, as adults are likely to have been previously exposed to RSV, resulting in baseline titer differences. Unfortunately, few RCTs stratify participants based on prior RSV infection, precluding analysis of this factor. We recommend that future RCTs account for baseline differences among subjects to provide a more accurate evaluation.
Vaccination is a highly effective measure to reduce disease burden. Beyond efficacy and safety, the economic aspect is also a critical factor to consider. Given that most RSV-related deaths occur in low- and middle-income countries, promoting RSV vaccines in these regions is particularly important. However, several barriers exist, including insufficient awareness of RSV, a lack of relevant national surveillance data, and the high costs associated with RSV diagnostic monitoring and related vaccine products [38]. Consequently, future efforts should focus on conducting cost-effectiveness evaluations for different vaccines to enhance immunization programs across various countries and regions.
This study encompasses not only the two subunit vaccines already available on the market but also those currently undergoing RCTs. In terms of target populations, besides the primary groups for RSV vaccine development—children, pregnant women, and the elderly—it is also essential to include data from healthy adults who have received the vaccine. This comprehensive approach aims to provide evidence for potentially expanding the vaccination population in the future, thereby further promoting herd immunity, which is crucial for the prevention of infectious diseases.
However, several potential limitations should be noted. Firstly, the number of studies included for combining different vaccine efficacy outcomes was relatively small, so the combined results should be interpreted with caution. Secondly, the evaluation methods for vaccine immunogenicity outcomes, such as neutralizing antibody titers and T cell responses, were varied. We did not evaluate T cell responses post-vaccination, primarily because few studies reported data on this aspect. Thirdly, different studies employed different methods to detect neutralizing antibody levels, potentially leading to high heterogeneity. Lastly, some of the included studies (phase I/II trials) had a small number of participants, which may result in the safety outcomes of the vaccine being either underestimated or overestimated.

5. Conclusions

This meta-analysis shows that subunit vaccines are effective, safe, and boost immune responses. They significantly reduce severe RSV infections without increasing serious adverse events. These findings support the inclusion of subunit RSV vaccines in immunization programs, with attention paid to local adverse reactions. Future studies should explore cost-effectiveness for wider use.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/vaccines12080879/s1. Table S1: Search strategy; Table S2: Studies excluded based on full text; Table S3: Quality Assessment of included studies; Table S4: Evaluation of the quality of evidence using GRADE system for outcomes; Figure S1: Subgroup analysis for RSV-ARI, RSV-LRTI, RSV-SLRTI; Figure S2: Sensitivity analysis for RSV-ARI, RSV-LRTI, RSV-SLRTI; Figure S3: Subgroup analysis for SAE; Figure S4: Sensitivity analysis for SAE; Figure S5: Funnel plot of SAE; Figure S6: Subgroup analysis for nAb; Figure S7: Sensitivity analysis for nAb; Figure S8: Funnel plot of log-transformed neutralizing antibody.

Author Contributions

Y.W., Y.L. (Yuqiong Lu) and Y.L. (Yun Lu) conceived and designed the study. Y.W., Y.B. and B.Z. completed the collection of relevant studies and data extraction. Y.L. (Yuqiong Lu), F.C. and Y.L. (Yun Lu) performed the statistical analysis and interpretation of the data. Y.W., Y.L. (Yuqiong Lu), F.C., Y.L. (Yun Lu), Y.B. and B.Z. drafted the manuscript and reviewed it critically for important intellectual content. All authors have read and agreed to the published version of the manuscript and have approved the final version. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Y.W. and Y.L. (Yuqiong Lu) contributed equally to this work. F.C. and Y.L. (Yun Lu) contributed equally to this work.

Funding

This study has been funded by The General Project of Philosophy and Social Science Research in Colleges and Universities of Jiangsu Province (No. 2024SJYB0073).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data presented in this study are available in the article.

Conflicts of Interest

The authors declare no conflicts of interest in this work.

References

  1. Graham, B.S.; Anderson, L.J. Challenges and opportunities for respiratory syncytial virus vaccines. Curr. Top. Microbiol. Immunol. 2013, 372, 391–404. [Google Scholar] [PubMed]
  2. Nam, H.H.; Ison, M.G. Respiratory syncytial virus infection in adults. BMJ 2019, 366, l5021. [Google Scholar] [CrossRef] [PubMed]
  3. Li, Y.; Wang, X.; Blau, D.M.; Caballero, M.T.; Feikin, D.R.; Gill, C.J.; Madhi, S.A.; Omer, S.B.; Simões, E.A.F.; Campbell, H. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis. Lancet 2022, 399, 2047–2064. [Google Scholar] [CrossRef] [PubMed]
  4. Savic, M.; Penders, Y.; Shi, T.; Branche, A.; Pirçon, J.Y. Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: A systematic literature review and meta-analysis. Influenza Other Respir. Viruses 2023, 17, e13031. [Google Scholar] [CrossRef] [PubMed]
  5. Gill, C.J.; Mwananyanda, L.; MacLeod, W.B.; Kwenda, G.; Pieciak, R.; Mupila, Z.; Murphy, C.; Chikoti, C.; Forman, L.; Berklein, F. Infant deaths from respiratory syncytial virus in Lusaka, Zambia from the ZPRIME study: A 3-year, systematic, post-mortem surveillance project. Lancet Glob. Health 2022, 10, e269–e277. [Google Scholar] [CrossRef]
  6. Cohen, C.; Zar, H.J. Deaths from RSV in young infants-the hidden community burden. Lancet Glob. Health 2022, 10, e169–e170. [Google Scholar] [CrossRef]
  7. Gatt, D.; Martin, I.; AlFouzan, R.; Moraes, T.J. Prevention and Treatment Strategies for Respiratory Syncytial Virus (RSV). Pathogens 2023, 12, 154. [Google Scholar] [CrossRef]
  8. Tam, C.C.; Yeo, K.T.; Tee, N.; Lin, R.; Mak, T.M.; Thoon, K.C.; Jit, M.; Yung, C.F. Burden and Cost of Hospitalization for Respiratory Syncytial Virus in Young Children, Singapore. Emerg. Infect. Dis. 2020, 26, 1489–1496. [Google Scholar] [CrossRef] [PubMed]
  9. Mazur, N.I.; Terstappen, J.; Baral, R.; Bardají, A.; Beutels, P.; Buchholz, U.J.; Cohen, C.; Crowe, J.E., Jr.; Cutland, C.L.; Eckert, L. Respiratory syncytial virus prevention within reach: The vaccine and monoclonal antibody landscape. Lancet Infect. Dis. 2023, 23, e2–e21. [Google Scholar] [CrossRef] [PubMed]
  10. Melgar, M.; Britton, A.; Roper, L.E.; Talbot, H.K.; Long, S.S.; Kotton, C.N.; Havers, F.P. Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023. Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg. 2023, 23, 1631–1640. [Google Scholar] [CrossRef]
  11. Simoes, E.A.; Tan, D.H.; Ohlsson, A.; Sales, V.; Wang, E.E. Respiratory syncytial virus vaccine: A systematic overview with emphasis on respiratory syncytial virus subunit vaccines. Vaccine 2001, 20, 954–960. [Google Scholar] [CrossRef] [PubMed]
  12. Shan, J.; Britton, P.N.; King, C.L.; Booy, R. The immunogenicity and safety of respiratory syncytial virus vaccines in development: A systematic review. Influenza Other Respir. Viruses 2021, 15, 539–551. [Google Scholar] [CrossRef] [PubMed]
  13. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. Reprint--preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Phys. Ther. 2009, 89, 873–880. [Google Scholar] [CrossRef] [PubMed]
  14. Sterne, J.A.C.; Savović, J.; Page, M.J.; Elbers, R.G.; Blencowe, N.S.; Boutron, I.; Cates, C.J.; Cheng, H.Y.; Corbett, M.S.; Eldridge, S.M. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 2019, 366, l4898. [Google Scholar] [CrossRef] [PubMed]
  15. Guyatt, G.H.; Oxman, A.D.; Vist, G.E.; Kunz, R.; Falck-Ytter, Y.; Alonso-Coello, P.; Schünemann, H.J. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008, 336, 924–926. [Google Scholar] [CrossRef] [PubMed]
  16. Higgins, J.P.T.; Thomas, J.; Chandler, J.; Cumpston, M.; Li, T.; Page, M.J.; Welch, V.A. (Eds.) Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (Updated August 2023); Cochrane: Hoboken, NJ, USA, 2023; Available online: www.training.cochrane.org/handbook (accessed on 30 May 2024).
  17. Bebia, Z.; Reyes, O.; Jeanfreau, R.; Kantele, A.; De Leon, R.G.; Sánchez, M.G.; Banooni, P.; Gardener, G.J.; Rasero, J.L.B.; Pardilla, M.B.E. Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial. J. Infect. Dis. 2023, 228, 299–310. [Google Scholar] [CrossRef] [PubMed]
  18. Cheng, X.; Zhao, G.; Dong, A.; He, Z.; Wang, J.; Jiang, B.; Wang, B.; Wang, M.; Huai, X.; Zhang, S.; et al. A First-in-Human Trial to Evaluate the Safety and Immunogenicity of a G Protein-Based Recombinant Respiratory Syncytial Virus Vaccine in Healthy Adults 18-45 Years of Age. Vaccines 2023, 11, 999. [Google Scholar] [CrossRef] [PubMed]
  19. Falloon, J.; Ji, F.; Curtis, C.; Bart, S.; Sheldon, E.; Krieger, D.; Dubovsky, F.; Lambert, S.; Takas, T.; Villafana, T.; et al. A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant. Vaccine 2016, 34, 2847–2854. [Google Scholar] [CrossRef] [PubMed]
  20. Falsey, A.R.; Walsh, E.E.; Scott, D.A.; Gurtman, A.; Zareba, A.; Jansen, K.U.; Gruber, W.C.; Dormitzer, P.R.; Swanson, K.A.; Jiang, Q. Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults with Concomitant Inactivated Influenza Vaccine. J. Infect. Dis. 2022, 225, 2056–2066. [Google Scholar] [CrossRef]
  21. Kampmann, B.; Madhi, S.A.; Munjal, I.; Simoes, E.A.F.; Pahud, B.A.; Llapur, C.; Baker, J.; Perez Marc, G.; Radley, D.; Shittu, E. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. N. Engl. J. Med. 2023, 388, 1451–1464. [Google Scholar] [CrossRef]
  22. Kotb, S.; Haranaka, M.; Folschweiller, N.; Nakanwagi, P.; Verheust, C.; De Schrevel, N.; David, M.P.; Mesaros, N.; Hulstrøm, V. Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial. Respir. Investig. 2023, 61, 261–269. [Google Scholar] [CrossRef]
  23. Langley, J.M.; Aggarwal, N.; Toma, A.; Halperin, S.A.; McNeil, S.A.; Fissette, L.; Dewé, W.; Leyssen, M.; Toussaint, J.F.; Dieussaert, I. A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine with or without Alum Adjuvant. J. Infect. Dis. 2017, 215, 24–33. [Google Scholar] [CrossRef]
  24. Langley, J.M.; MacDonald, L.D.; Weir, G.M.; MacKinnon-Cameron, D.; Ye, L.; McNeil, S.; Schepens, B.; Saelens, X.; Stanford, M.M.; Halperin, S.A. A Respiratory Syncytial Virus Vaccine Based on the Small Hydrophobic Protein Ectodomain Presented with a Novel Lipid-Based Formulation Is Highly Immunogenic and Safe in Adults: A First-in-Humans Study. J. Infect. Dis. 2018, 218, 378–387. [Google Scholar] [CrossRef] [PubMed]
  25. Leroux-Roels, G.; De Boever, F.; Maes, C.; Nguyen, T.L.; Baker, S.; Gonzalez Lopez, A. Safety and immunogenicity of a respiratory syncytial virus fusion glycoprotein F subunit vaccine in healthy adults: Results of a phase 1, randomized, observer-blind, controlled, dosage-escalation study. Vaccine 2019, 37, 2694–2703. [Google Scholar] [CrossRef]
  26. Leroux-Roels, I.; Davis, M.G.; Steenackers, K.; Essink, B.; Vandermeulen, C.; Fogarty, C.; Andrews, C.P.; Kerwin, E.; David, M.P.; Fissette, L. Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial. J. Infect. Dis. 2023, 227, 761–772. [Google Scholar] [CrossRef]
  27. Papi, A.; Ison, M.G.; Langley, J.M.; Lee, D.G.; Leroux-Roels, I.; Martinon-Torres, F.; Schwarz, T.F.; van Zyl-Smit, R.N.; Campora, L.; Dezutter, N. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. N. Engl. J. Med. 2023, 388, 595–608. [Google Scholar] [CrossRef] [PubMed]
  28. Schmoele-Thoma, B.; Zareba, A.M.; Jiang, Q.; Maddur, M.S.; Danaf, R.; Mann, A.; Eze, K.; Fok-Seang, J.; Kabir, G.; Catchpole, A. Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study. N. Engl. J. Med. 2022, 386, 2377–2386. [Google Scholar] [CrossRef] [PubMed]
  29. Schwarz, T.F.; Johnson, C.; Grigat, C.; Apter, D.; Csonka, P.; Lindblad, N.; Nguyen, T.L.; Gao, F.F.; Qian, H.; Tullio, A.N. Three Dose Levels of a Maternal Respiratory Syncytial Virus Vaccine Candidate Are Well Tolerated and Immunogenic in a Randomized Trial in Nonpregnant Women. J. Infect. Dis. 2022, 225, 2067–2076. [Google Scholar] [CrossRef]
  30. Schwarz, T.F.; McPhee, R.A.; Launay, O.; Leroux-Roels, G.; Talli, J.; Picciolato, M.; Gao, F.; Cai, R.; Nguyen, T.L.; Dieussaert, I. Immunogenicity and Safety of 3 Formulations of a Respiratory Syncytial Virus Candidate Vaccine in Nonpregnant Women: A Phase 2, Randomized Trial. J. Infect. Dis. 2019, 220, 1816–1825. [Google Scholar] [CrossRef]
  31. Simões, E.A.F.; Center, K.J.; Tita, A.T.N.; Swanson, K.A.; Radley, D.; Houghton, J.; McGrory, S.B.; Gomme, E.; Anderson, M.; Roberts, J.P. Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy. N. Engl. J. Med. 2022, 386, 1615–1626. [Google Scholar] [CrossRef]
  32. Walsh, E.E.; Falsey, A.R.; Scott, D.A.; Gurtman, A.; Zareba, A.M.; Jansen, K.U.; Gruber, W.C.; Dormitzer, P.R.; Swanson, K.A.; Radley, D. A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine. J. Infect. Dis. 2022, 225, 1357–1366. [Google Scholar] [CrossRef] [PubMed]
  33. Walsh, E.E.; Perez Marc, G.; Zareba, A.M.; Falsey, A.R.; Jiang, Q.; Patton, M.; Polack, F.P.; Llapur, C.; Doreski, P.A.; Ilangovan, K.; et al. Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults. N. Engl. J. Med. 2023, 388, 1465–1477. [Google Scholar] [CrossRef] [PubMed]
  34. Roberts, J.N.; Graham, B.S.; Karron, R.A.; Munoz, F.M.; Falsey, A.R.; Anderson, L.J.; Marshall, V.; Kim, S.; Beeler, J.A. Challenges and opportunities in RSV vaccine development: Meeting report from FDA/NIH workshop. Vaccine 2016, 34, 4843–4849. [Google Scholar] [CrossRef]
  35. Yu, J.; Powers, J.H., 3rd; Vallo, D.; Falloon, J. Evaluation of Efficacy Endpoints for a Phase IIb Study of a Respiratory Syncytial Virus Vaccine in Older Adults Using Patient-Reported Outcomes with Laboratory Confirmation. Value Health J. Int. Soc. Pharmacoecon. Outcomes Res. 2020, 23, 227–235. [Google Scholar] [CrossRef] [PubMed]
  36. World Health Organization. WHO Preferred Product Characteristics for Respiratory Syncytial Virus (RSV) Vaccines. Available online: https://www.who.int/publications/i/item/WHO-IVB-17.11 (accessed on 30 May 2024).
  37. Ruckwardt, T.J.; Morabito, K.M.; Phung, E.; Crank, M.C.; Costner, P.J.; Holman, L.A.; Chang, L.A.; Hickman, S.P.; Berkowitz, N.M.; Gordon, I.J. Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: A phase 1, randomised, open-label, dose-escalation clinical trial. Lancet Respir. Med. 2021, 9, 1111–1120. [Google Scholar] [CrossRef] [PubMed]
  38. Ruckwardt, T.J. The road to approved vaccines for respiratory syncytial virus. NPJ Vaccines 2023, 8, 138. [Google Scholar] [CrossRef] [PubMed]
Vaccines 12 00879 g001
Figure 1. PRISMA flow diagram.
Figure 1. PRISMA flow diagram.
Vaccines 12 00879 g001
Vaccines 12 00879 g002
Figure 2. Forest plot of efficacy in vaccine and placebo groups of RSV-ARI [27,28,33].
Figure 2. Forest plot of efficacy in vaccine and placebo groups of RSV-ARI [27,28,33].
Vaccines 12 00879 g002
Vaccines 12 00879 g003
Figure 3. Forest plot of efficacy in vaccine and placebo groups of RSV-LRTI [21,27,31,33].
Figure 3. Forest plot of efficacy in vaccine and placebo groups of RSV-LRTI [21,27,31,33].
Vaccines 12 00879 g003
Vaccines 12 00879 g004
Figure 4. Forest plot of efficacy in vaccine and placebo groups of RSV-SLRTI [21,27,31].
Figure 4. Forest plot of efficacy in vaccine and placebo groups of RSV-SLRTI [21,27,31].
Vaccines 12 00879 g004
Vaccines 12 00879 g005
Figure 5. Forest plot of SAEs in vaccine and placebo groups [17,19,20,21,22,26,27,29,30,31,32,33].
Figure 5. Forest plot of SAEs in vaccine and placebo groups [17,19,20,21,22,26,27,29,30,31,32,33].
Vaccines 12 00879 g005
Vaccines 12 00879 g006
Figure 6. Forest plot of GMT values of log-transformed neutralizing antibodies [17,20,22,23,25,26,27,28,29,30,31,32].
Figure 6. Forest plot of GMT values of log-transformed neutralizing antibodies [17,20,22,23,25,26,27,28,29,30,31,32].
Vaccines 12 00879 g006
Table 1. Summary of research articles.
Table 1. Summary of research articles.
NoFirst Author,
Year		CountryPhaseTarget Population;
Age		Sample SizeSex
(% Female)		Vaccine
Name		AdjuvantEfficacySafetyImmunogenicity
RSV-ARIRSV-LRTIRSV-SRLILocal or
System AEs		Serious AEsGMT
1Bebia Z, 2023 [17]multicenterphase 2Pregnant Women; 18–40 y143100RSVPreF3NoneNRNRNRYESYESYES
2Cheng X, 2023 [18]Australiaphase 1Adults; 18–45 y6076.7BARS13cyclosporine ANRNRNRYESYESNR
3Falloon J, 2016 [19]United States phase 1aOld Adults; ≥60 y4451.2RSV sFglucopyranosyl lipid ANRNRNRYESYESNR
4Falsey AR, 2022 [20]United States phase 1/2Old Adults; 65–85 y8163RSVpreFNoneNRNRNRYESYESYES
5Kampmann B, 2023 [21]multicenterphase 3Pregnant Women; 18–49 y7392100RSVpreFNoneNRYESYESYESYESNR
6Kotb S, 2023 [22]Japanphase 1Old Adults; 60–80 y4050RSVPreF3AS01 ENRNRNRYESYESYES
7Langley JM, 2017 [23]Canadaphase 1Adults; 18–44 y320RSV-PreFNoneNRNRNRYESYESYES
8Langley JM, 2018 [24]Canadaphase 1Old Adults; 50–64 y1672.5DPX-RSVNoneNRNRNRYESYESNR
9Leroux-Roels G, 2019 [25]Belgiumphase 1Adults; 18–45 y4866.7RSV FAl(OH)3NRNRNRYESYESYES
10Leroux-Roels I, 2023 [26]multicenterphase 1/2Old Adults; 60–80 y20157.2RSVPreF3AS01 ENRNRNRYESYESYES
11Papi A, 2023 [27]multicenterphase 3Old Adults; ≥60 y24,96651.7RSVpreF3AS01 EYESYESYESYESYESYES
12Schmoele-Thoma B, 2022 [28]United Kingdomphase 2aAdults; 18–50 y7029RSVpreFNoneYESNRNRYESYESYES
13Schwarz TF, 2022 [29]multicenterphase 1/2Adults; 18–45 y252100RSVPreF3NoneNRNRNRYESYESYES
14Schwarz TF, 2019 [30]multicenterphase 2Adults; 18–45 y201100RSVpreFNoneNRNRNRYESYESYES
15Simões EAF, 2022 [31]multicenterphase 2bPregnant Women; 18–49 y158100RSVpreFNoneNRYESYESYESYESYES
16Walsh EE, 2022 [32]United Statesphase 1/2Adults; 18–49 y 10763.6RSVpreFNoneNRNRNRYESYESYES
17Walsh EE, 2023 [33]multicenterphase 3Old Adults; ≥60 y34,28449.2RSVpreFNoneYESYESNRYESYESNR
RSV: respiratory syncytial virus; ARI: acute respiratory infection; LRTI: lower respiratory tract infection; SLRTI: severe lower respiratory tract infection; GMT: geometric mean titer; AE: adverse event; YES: this study reported on the relevant outcomes; NR: this study did not report on the relevant outcomes; y: year.
Table 2. The incidence of adverse events among the intervention group versus the control group.
Table 2. The incidence of adverse events among the intervention group versus the control group.
Adverse EventsNo. of
Studies		Reactions/TotalRR (95% CI)Heterogeneity I2 (%)p-Heterogeneity
InterventionControl
Local adverse events (any)71932/5625974/55433.58 (2.00, 6.41)97.50.000
Systemic adverse events(any)71665/56251400/55341.40 (1.05, 1.85)91.00.000
Pain162320/8895664/87724.00 (2.92, 5.49)82.90.000
Redness13465/885183/87245.49 (4.36, 6.91)42.10.055
Swelling12334/795776/78373.75 (1.90, 7.38)60.90.003
Fatigue152780/88872317/87641.23 (1.05, 1.44)67.30.000
Headaches152097/88871685/87641.37 (1.08, 1.74)86.60.000
Myalgia111447/7706943/75851.52 (1.41, 1.63)33.60.130
Nausea9923/8510882/87741.05 (0.97, 1.15)48.90.048
Pyrexia10333/8598207/84791.91 (1.10, 3.32)75.50.000
Arthralgia7488/4022428/39811.14 (1.01, 1.29)12.60.334
RR: risk ratio; CI: confidence interval.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Wu, Y.; Lu, Y.; Bai, Y.; Zhu, B.; Chang, F.; Lu, Y. Efficacy, Safety, and Immunogenicity of Subunit Respiratory Syncytial Virus Vaccines: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Vaccines 2024, 12, 879. https://doi.org/10.3390/vaccines12080879

AMA Style

Wu Y, Lu Y, Bai Y, Zhu B, Chang F, Lu Y. Efficacy, Safety, and Immunogenicity of Subunit Respiratory Syncytial Virus Vaccines: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Vaccines. 2024; 12(8):879. https://doi.org/10.3390/vaccines12080879

Chicago/Turabian Style

Wu, Yuhang, Yuqiong Lu, Yuwei Bai, Bingde Zhu, Feng Chang, and Yun Lu. 2024. "Efficacy, Safety, and Immunogenicity of Subunit Respiratory Syncytial Virus Vaccines: Systematic Review and Meta-Analysis of Randomized Controlled Trials" Vaccines 12, no. 8: 879. https://doi.org/10.3390/vaccines12080879

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop